AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Up 78.6% in January

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,470,000 shares, an increase of 78.6% from the January 15th total of 822,900 shares. Based on an average daily volume of 677,900 shares, the days-to-cover ratio is currently 2.2 days.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, January 10th.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO traded down $0.19 during mid-day trading on Monday, reaching $10.34. The company's stock had a trading volume of 196,192 shares, compared to its average volume of 857,383. The stock has a market capitalization of $418.46 million, a P/E ratio of -1.84 and a beta of 0.60. AngioDynamics has a 1-year low of $5.26 and a 1-year high of $13.50. The stock has a 50-day moving average of $10.56 and a two-hundred day moving average of $8.34.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business's revenue was down .1% on a year-over-year basis. During the same period last year, the company posted ($0.05) EPS. Analysts predict that AngioDynamics will post -0.37 EPS for the current fiscal year.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares of the company's stock, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.40% of the company's stock.

Institutional Trading of AngioDynamics

Several large investors have recently added to or reduced their stakes in ANGO. SBI Securities Co. Ltd. acquired a new stake in AngioDynamics during the fourth quarter worth $28,000. R Squared Ltd purchased a new stake in shares of AngioDynamics in the 4th quarter valued at approximately $49,000. US Bancorp DE lifted its holdings in shares of AngioDynamics by 1,938.0% in the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock worth $61,000 after acquiring an additional 6,376 shares during the last quarter. Quarry LP boosted its position in shares of AngioDynamics by 40.9% during the 3rd quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier's stock worth $66,000 after purchasing an additional 2,471 shares during the period. Finally, CWM LLC boosted its position in shares of AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock worth $76,000 after purchasing an additional 8,832 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.